Atrecaincis A Clinical Stage Biopharmaceutical Company Based In San Carloscaliforniafounded In 2010Atreca Focuses On Discovering And Developing Antibody Based Immunotherapies For Solid Tumors And Infectious Diseasesthe Company Employs Around 90 Individuals And Utilizes Proprietary Technologies To Analyze Immune Responses In Patientswhich Helps Identify Novel Therapeutic Targets Atreca S Product Pipeline Includes Atrc 101A Monoclonal Antibody Targeting Tumor Specific Antigens In Various Cancerscurrently In Phase Ib Trialsanother Key Candidateatrc 501 Mam01Aims To Prevent Malaria By Targeting The Circumsporozoite Protein Ofplasmodium Falciparum Developed In Collaboration With The Bill & Melinda Gates Medical Research Institutethe Company Also Has Preclinical Programs Focused On Antibody Drug Conjugates And Bispecific T Cell Engagersatreca Collaborates With Xencorincto Develop Cd3 Bispecific Antibodies For Oncologyenhancing Its Innovative Approach To Cancer Treatment
No conferences found for this company.
| Company Name | Atreca Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
